Lukas Scheibler - Apr 1, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
CHIEF INNOVATION OFFICER
Signature
/s/ David Watson, attorney-in-fact for Lukas Scheibler
Stock symbol
APLS
Transactions as of
Apr 1, 2022
Transactions value $
-$473,635
Form type
4
Date filed
4/4/2022, 05:03 PM
Previous filing
Feb 15, 2022
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $159K +11.5K +22.01% $13.85 63.7K Apr 1, 2022 Direct F1
transaction APLS Common Stock Sale -$633K -11.5K -18.04% $55.05 52.2K Apr 1, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -11.5K -17.69% $0.00 53.5K Apr 1, 2022 Common Stock 11.5K $13.85 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from 10B5-1 trading plan.
F2 The sale price range within $1.00. Max. $55.12 - Min. $55.00
F3 This represents a stock option grant made on 02/08/2019 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.